loading page

Successful Treatment of Relapsed Chronic Lymphocytic Leukemia with Venetoclax in a Patient with Severe Chronic Kidney Disease
  • +7
  • Hiroyuki Sugiura,
  • Nobuo Sezaki,
  • Tatsunori Ishikawa,
  • Taiga Kuroi,
  • Sachiyo Okamoto,
  • Naho Nomura,
  • Taro Masunari,
  • Yukio Nakasako,
  • Toru Kiguchi,
  • Mitsune Tanimoto
Hiroyuki Sugiura
Chugoku Chuo Byoin

Corresponding Author:[email protected]

Author Profile
Nobuo Sezaki
Chugoku Chuo Byoin
Author Profile
Tatsunori Ishikawa
Chugoku Chuo Byoin
Author Profile
Taiga Kuroi
Chugoku Chuo Byoin
Author Profile
Sachiyo Okamoto
Chugoku Chuo Byoin
Author Profile
Naho Nomura
Chugoku Chuo Byoin
Author Profile
Taro Masunari
Chugoku Chuo Byoin
Author Profile
Yukio Nakasako
Chugoku Chuo Byoin
Author Profile
Toru Kiguchi
Dokkyo Medical University Saitama Medical Center
Author Profile
Mitsune Tanimoto
Chugoku Chuo Byoin
Author Profile

Abstract

Venetoclax is a promising new drug for relapsed or refractory chronic lymphocytic leukemia (CLL). However, venetoclax use had not been reported in severe chronic kidney disease (CKD) patients. We report the first case of relapsed CLL in a severe CKD patient that was successfully treated with venetoclax.
14 Dec 2021Submitted to Clinical Case Reports
14 Dec 2021Assigned to Editor
14 Dec 2021Submission Checks Completed
23 Dec 2021Reviewer(s) Assigned
16 Mar 2022Review(s) Completed, Editorial Evaluation Pending
25 Mar 2022Editorial Decision: Accept
Apr 2022Published in Clinical Case Reports volume 10 issue 4. 10.1002/ccr3.5735